- Report
- June 2025
- 150 Pages
Global
From €2383EUR$2,699USD£2,068GBP
- Report
- June 2025
- 400 Pages
Global
From €4370EUR$4,949USD£3,792GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2463EUR$2,789USD£2,137GBP
- Report
- June 2025
- 200 Pages
Global
From €2463EUR$2,789USD£2,137GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2463EUR$2,789USD£2,137GBP
- Report
- May 2025
- 99 Pages
Global
From €3500EUR$4,246USD£3,144GBP
- Report
- April 2025
- 86 Pages
Global
From €3500EUR$4,246USD£3,144GBP
- Report
- April 2025
- 130 Pages
Global
From €3640EUR$4,123USD£3,159GBP
€4282EUR$4,850USD£3,716GBP
- Report
- April 2025
- 130 Pages
Global
From €3640EUR$4,123USD£3,159GBP
€4282EUR$4,850USD£3,716GBP
- Report
- March 2025
- 210 Pages
Global
From €4410EUR$4,995USD£3,827GBP
- Report
- April 2025
- 200 Pages
United States
From €2199EUR$2,490USD£1,908GBP
- Report
- June 2025
- 123 Pages
North America
From €2648EUR$2,999USD£2,298GBP
- Report
- August 2025
- 122 Pages
North America
From €2648EUR$2,999USD£2,298GBP
- Report
- August 2018
- 340 Pages
Global
From €3089EUR$3,499USD£2,681GBP
- Report
- November 2020
- 260 Pages
Global
From €2428EUR$2,750USD£2,107GBP
- Report
- December 2019
- 165 Pages
Global
From €2428EUR$2,750USD£2,107GBP
- Report
- November 2023
- 171 Pages
Global
From €4106EUR$4,650USD£3,563GBP
- Report
- June 2023
- 80 Pages
United States
From €2649EUR$3,000USD£2,299GBP
- Report
- June 2023
- 150 Pages
Global
From €5254EUR$5,950USD£4,559GBP
- Drug Pipelines
- September 2022
- 280 Pages
Global
From €2119EUR$2,400USD£1,839GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more